Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
The National Association of Chain Drug Stores is praising the Federal Trade Commission's (FTC) unanimous, 5-0, vote on Monday to release the second interim staff report on the FTC's study of big ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
As many as 10 family-owned or pharmacies faced closure each day around the United States of America in 2024. This isn’t due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback